Verbatim response from ChatGPT
Short answer
- Because of the surge in demand for GLP‑1 drugs (semaglutide, tirzepatide, etc.), many compounding pharmacies began making “compounded GLP‑1” injections. The FDA has warned that compounding copies of these approved biologic drugs raises serious safety, quality, and legal issues and has issued enforcement actions (warning letters, stop‑ship requests) against some compounders.
- Who can still operate legally: the companies that actually hold FDA approval for GLP‑1 products (e.g., Novo Nordisk — Ozempic/Wegovy; Eli Lilly — Mounjaro/Zepbound), physicians who legally prescribe those approved products (including off‑label uses), and compounding operations that meet the specific legal/regulatory limits — primarily FDA‑registered 503B outsourcing facilities that follow CGMP and state‑licensed 503A pharmacies only when they meet narrow, patient‑specific compounding rules. Many compounding pharmacies that made bulk copies or shipped interstate have been told to stop.
What happened in more detail
- 2023–2024 demand spike led many compounding pharmacies to produce semaglutide/tirzepatide formulations to meet shortages or provide lower‑cost alternatives.
- The FDA’s concern: these are biologic peptide drugs produced via complex manufacturing and covered by approved biologics licenses. Making unapproved “copies,” compounding large batches, shipping interstate, or compounding without appropriate quality systems risks patient safety (purity, sterility, potency) and can violate the Federal Food, Drug, and Cosmetic Act (FDCA) and Public Health Service Act.
- The FDA issued public statements and enforcement letters telling some compounders to stop distribution and warning health care providers and patients about safety and legal risks. State boards of pharmacy and other agencies also acted in some cases.
Who is (generally) operating legally now
- Brand manufacturers with FDA approval: Novo Nordisk (Ozempic, Wegovy), Eli Lilly (Mounjaro, Zepbound), etc. Their products are legal when prescribed and dispensed properly.
- Licensed prescribers: doctors may legally prescribe FDA‑approved GLP‑1 drugs for on‑ or off‑label indications. Patients getting the approved drug via a pharmacy are on solid legal footing.
- 503A pharmacies (state‑licensed) may legally compound drugs under narrow, patient‑specific prescriptions — but FDA has warned that compounding copies of approved biologics is problematic and many state boards have tightened oversight.
- 503B outsourcing facilities that are registered with the FDA, follow current good manufacturing practices (CGMP), and comply with FDA requirements — these can legally produce certain compounded products in larger quantities, but producing unapproved copies of approved biologics still invites FDA scrutiny. You can verify 503B registration on the FDA’s Outsourcing Facility list.
How to protect yourself / what to check
- Prefer FDA‑approved products dispensed by a licensed pharmacy through a licensed prescriber (e.g., get Ozempic, Wegovy, Mounjaro from your doctor and a retail/ specialty pharmacy).
- If considering a compounded version, verify:
- Is the pharmacy a registered 503B outsourcing facility listed on FDA’s website? Or a state‑licensed 503A pharmacy compounding only for a specific patient?
- Does the pharmacy have credible accreditation (PCAB or similar), provide Certificates of Analysis, sterility testing, and lot records?
- Does your prescriber document a legitimate medical need for a compounded product?
- Avoid overseas or unverified online suppliers and “black‑market” vials — those are high risk legally and for patient safety.
If you have a specific compounder or clinic in mind Tell me the name and I’ll check whether it’s on the FDA’s outsourcing facility list or whether there are known FDA warning letters or state enforcement actions against it.